Madison-based cancer screening test maker Exact Sciences Corp. expects to turn profitable in 2024, the company’s chief financial officer and chief operating officer Jeff Elliott recently told investors.

“We’re very confident in delivering adjusted EBITDA profitability in 2024,” Elliott said during the company’s fourth-quarter earnings call on Feb. 22.

Elliott said the company intends to hit that milestone by incrementally growing revenue through sales of its flagship at-home colon cancer test Cologuard and by developing new products. It’s investing in areas like sales and marketing, and research and development on a multi-cancer test and Cologuard 2.0.

Click here to read the full article.